Considerations in the design of preclinical safety evaluation programs for novel therapeutics used in neurologic diseases.
D002986:Clinical Trials as Topic / Q000379:methods*; D006801:Humans; D009422:Nervous System Diseases / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use* / Q000633:toxicity*; D012107:Research Design
D018696:Neuroprotective Agents